18
Aug

As expected, Pfizer has submitted an early FDA application for palbociclib, beating a quick path to market with a breakthrough breast cancer treatment that could peak at nearly $3 billion a year.

…read more

Source: Pfizer hands in an early application for the blockbuster contender palbociclib

    

0 No comments